🔬 Technical comparison · NeoPeptidos

Peptide comparison

BPC-157 vs TB-500: how they differ and why they are combined

They are the two best-known peptides in tissue repair, and they are often studied together. But they act through distinct, complementary mechanisms: understanding them explains why the "BPC + TB" combo is so popular.

Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.

Tabla comparativa

  BPC-157TB-500
NaturePentadecapeptide (15 aa) from a gastric proteinSynthetic fragment of thymosin β4
Mecanismo principalAngiogenesis (VEGF), nitric oxide, repair signalingG-actin binding and cell migration
Research focusTendon, ligament, muscle and digestive mucosaProgenitor migration, angiogenesis, cardiac tissue
Rasgo distintivoRelative stability in gastric mediumBroad tissue diffusion
EvidenciaMostly preclinicalMostly preclinical

Analysis: how they differ

BPC-157 acts mainly through angiogenesis (involving VEGF) and local repair signaling, with an uncommon trait: some stability in gastric medium. TB-500, derived from thymosin β4, regulates the cytoskeleton through actin binding, the basis of cell migration toward the damaged area.

The reason for combining them is complementarity: one directs blood supply and local repair signaling, the other cell motility and migration. It is important to frame the evidence: for both it is mostly preclinical, and their translation to humans is a matter of research.

💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.

Frequently asked questions

What is the difference between BPC-157 and TB-500?

BPC-157 is a pentadecapeptide that acts mainly through angiogenesis (VEGF) and repair signaling; TB-500, derived from thymosin β4, regulates the cytoskeleton through actin binding and favors cell migration. They are distinct, complementary mechanisms.

Why are BPC-157 and TB-500 combined?

Because they cover complementary phases of repair: BPC-157 directs blood supply and local signaling, and TB-500 cell migration toward the damaged tissue. That complementarity is the logic of the popular "combo".

Is the evidence clinical or preclinical?

For both compounds the evidence is mostly preclinical (animal and in vitro models). Their translation to humans is an active area of research.

Otras comparativas

Explore these compounds in the catalog

Purity ≥99% verificada por HPLC and batch COA.

View full catalog →
Educational content for scientific purposes. Preclinical and clinical evidence are distinguished; it does not constitute medical advice or a recommendation for use. NeoPeptidos products are sold labeled for scientific research.